Agile Therapeutics Q1 2023 Earnings Report

Agile Therapeutics EPS Results

• Actual EPS: -$7.76
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Agile Therapeutics Revenue Results

• Actual Revenue: $3.81 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Agile Therapeutics Announcement Details

• Quarter: Q1 2023
• Date: 5/11/2023
• Time: N/A

Agile Therapeutics (NASDAQ:AGRX), a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.